← Back to home

LOCALLY ADVANCED UNRESECTABLE GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA CANCER

Clinical trials for LOCALLY ADVANCED UNRESECTABLE GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA CANCER explained in plain language.

Never miss a new study

Get alerted when new LOCALLY ADVANCED UNRESECTABLE GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA CANCER trials appear

Sign up with your email to follow new studies for LOCALLY ADVANCED UNRESECTABLE GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

Breakthrough cancer drug offered early to eligible stomach cancer patients

Disease control AVAILABLE

This program provides early access to the drug zolbetuximab for people with advanced stomach or gastroesophageal junction cancer who haven't had prior treatment. It's for patients whose cancer tests positive for a specific protein called claudin18.2. Participants receive zolbetux…

Matched conditions: LOCALLY ADVANCED UNRESECTABLE GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA CANCER

Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control

Last updated Mar 27, 2026 12:39 UTC

LOCALLY ADVANCED UNRESECTABLE GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA CANCER

Get alerted when new LOCALLY ADVANCED UNRESECTABLE GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA CANCER trials appear

Breakthrough cancer drug offered early to eligible stomach cancer patients